# Study of Sivelestat Sodium in OPCABG

> **NCT07118930** · PHASE2 · RECRUITING · sponsor: **Affiliated Hospital of Nantong University** · enrollment: 62 (estimated)

## Conditions studied

- Coronary Heart Disease
- Coronary Artery Disease
- Coronary Arterial Disease (CAD)

## Interventions

- **DRUG:** Sivelestat Sodium injection 2 h after OPCABG for 72 h
- **DRUG:** Saline (0.9% NaCl)

## Key facts

- **NCT ID:** NCT07118930
- **Lead sponsor:** Affiliated Hospital of Nantong University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-08-01
- **Primary completion:** 2027-07-31
- **Final completion:** 2027-07-31
- **Target enrollment:** 62 (ESTIMATED)
- **Last updated:** 2025-08-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07118930

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07118930, "Study of Sivelestat Sodium in OPCABG". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07118930. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*